Company
Accriva Diagnostics
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
7
Received Nov 1, 2025 to Nov 20, 2026
Recall records
8
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$15.5M
2 Form D offerings, 2013 to 2015
Equity
$15.5M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $15.5M raised of $18.9M sought, first sale Feb 27, 2015, 3 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- Accriva Diagnostics Holdings, Inc.
- Headquarters
- San Diego, California
- Incorporated
- Delaware in 2010
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1505837 ↗
Executives, directors and promoters
As listed on the latest Form D.
11 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Accriva Diagnostics.
Latest FDA decisions
- Tenderfoot510(k)
K223352 · Decided Mar 2, 2023 · 120 days after receipt
Device type: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature (FMK) · General & Plastic Surgery
K202101 · Decided Dec 29, 2021 · 518 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
K193041 · Decided Nov 22, 2019 · 22 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
7
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
4
57% of reports
Injury reports
2
29% of reports
Death reports
1
14% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 1 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 1 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 1 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 2 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 2 | 1 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
2 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103Open, Classified
Z-0317-2027 · Started Sep 14, 2026 · Posted by FDA Oct 30, 2026
Reason given: Microcoagulation test used to evaluate low dose heparin anticoagulation has a mispositioned or absent clot activating reagent, which may result in out-of-range high error code, or erroneously high results, which may lead retest, or overestimation of patient's anticoagulation, leading to inadequate anticoagulant...
Cause as FDA categorized it: Process control · Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA)
- directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2Open, Classified
Z-2460-2026 · Started Apr 30, 2026 · Posted by FDA Jun 16, 2026
Reason given: Assayed Whole blood control contains labeling with incorrect performance range.
Cause as FDA categorized it: Process control · Device type: Plasma, Coagulation Control (GGN)
Z-0880-2026 · Started Nov 5, 2025 · Posted by FDA Dec 3, 2025
Reason given: Test cuvettes, used with an assay for monitoring heparin anticoagulation, may have a foreign object that has sharp edges and could pose a risk of injury if not detected prior to handling.
Cause as FDA categorized it: Packaging process control · Device type: Activated Whole Blood Clotting Time (JBP)
5 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.